The two radiopharmaceuticals are 177Lu-vipivotide tetraxetan (previously known as 177Lu-PSMA-617, and sold under the commercial name of Pluvicto) and 177Lu-oxodotreotide (sold under the commercial name of Lutathera) for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancers and certain digestive tract cancers, respectively (10, 11). Here, FOLH1 is linked to prostate carcinoma.